Publications by authors named "B Reardon"
Article Synopsis
- The introduction of immune checkpoint blockade (ICB) has greatly improved treatment outcomes for advanced melanoma, but many patients still become resistant to it due to unclear reasons.
- Although combining different ICB therapies has been shown to enhance response rates, it also comes with increased toxicity for patients.
- An analysis of tumor samples from ICB-naïve patients revealed that high genomic heterogeneity and low ploidy can identify those who are intrinsically resistant to aPD-1, leading to a predictive model that may help tailor treatment strategies.
Importance: Aggressive thyroid carcinoma, including radioiodine refractory (RAIR) differentiated thyroid carcinoma (DTC), medullary thyroid carcinoma (MTC), and anaplastic thyroid carcinoma (ATC), are associated with significant morbidity and mortality and have limited therapeutic options. Distinct immune profiles have been identified in thyroid cancer subtypes suggesting they may be susceptible to immune checkpoint inhibition.
Objective: To evaluate the efficacy of anti-programmed cell death 1 nivolumab and anti-cytotoxic lymphocyte-associated protein 4 ipilimumab in patients with aggressive thyroid carcinoma.
Background: Genomic tumour profiling has a crucial role in the management of patients with solid cancers, as it helps selecting and prioritising therapeutic interventions based on prognostic and predictive biomarkers, as well as identifying markers of hereditary cancers. Harmonised approaches to interpret the results of genomic testing are needed to support physicians in their decision making, prevent inequalities in precision medicine and maximise patient benefit from available cancer management options.
Methods: The European Society for Medical Oncology (ESMO) Translational Research and Precision Medicine Working Group assembled a group of international experts to propose recommendations for preparing clinical genomic reports for solid cancers.
Viscoelastic testing is increasingly being used in clinical and research settings to assess hemostasis. Indeed, there are potential situations in which viscoelastic testing is reportedly superior to standard routine laboratory testing for hemostasis. We report the current testing platforms and terminology, as well as providing a concise narrative review of the published evidence to guide its use in various clinical settings.
View Article and Find Full Text PDFArticle Synopsis
- The study examines the variety of structural variants (SVs) in melanoma and their role in cancer development, revealing differences across melanoma subtypes, such as frequency, size, and types of SVs.
- The researchers found specific SVs associated with chromothripsis events and their effects on important cancer genes, particularly those influencing topologically associated domains (TADs).
- They also discovered loss-of-function SVs in genes MRE11 and NBN that correlate with a particular mutational profile and suggest a potential vulnerability of melanoma cells to PARP inhibitors due to these genetic alterations.